Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1422-1433

  Richardson Harman, Nicola ^a   Mauck, Christine ^b   McGowan, Ian ^c   Anton, Peter ^d  

^a ALPHA STATCONSULT LLC   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE;

ACCURACY; ARTICLE; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; EX VIVO STUDY; EXPLANT; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VIVO STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM BIOPSY; REPRODUCIBILITY; RETROSPECTIVE STUDY; VIROGENESIS; VIRUS INFECTIVITY; VIRUS TITRATION;

ADMINISTRATION, RECTAL; ANALYSIS OF VARIANCE; ANILIDES; ANTI-INFECTIVE AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY; FEMALE; FURANS; GELS; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; RECTUM; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 84868529632     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0073     Document Type: Article

References (22)

1. McGowan I: Microbicides for HIV prevention: Reality or hope? Curr Opin Infect Dis 2010;23:26-31.
2. McGowan I: Rectal microbicides: Can we make them and will people use them? AIDS Behav 2011;15(Suppl 1):S66-7 1.
3. Hendrix CW, Cao YJ, and Fuchs EJ: Topical microbicides to prevent HIV: Clinical drug development challenges. Annu Rev Pharmacol Toxicol 2009;49:349-375.
4. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al.: Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4.
5. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE Jr, Fink A, et al.: A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 2005;192:1545-1556.
6. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, et al.: Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006;20:1237-1245.
7. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, et al.: First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 2011;6: e23243.
8. Anton P: A phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF [Abstract]. In 18th Conference on Retroviruses and Opportunistic Infections Boston 2011. Boston, 2011.
9. McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, Adler A, et al.: Characterization of baseline intestinal mu-cosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 2007;46:417-425.
10. Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, Price C, et al.: Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods 2003;279:17-31.
11. Herrera C, Cranage M, McGowan I, Anton P, and Shattock RJ: Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009;53:1797-1807.
12. Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, et al.: HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010;3:280-290.
13. Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, Dezzutti CS, et al.: Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol 2009;47:3530-3539.
14. Yeh SH: Using the trapezoidal rule for the area under the curve calculation. SAS® Users Group International. 1991;27:229-227.
15. Flint SJ, Enquist LW, Racaniello VR, and Skalka AM: Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses, 2nd ed. ASM Press, Washington, DC, 2004.
16. Tsai WP, Conley SR, Kung HF, Garrity RR, and Nara PL: Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology 1996;226:205-216.
17. Tiwari GT: Bioanalytical method validation: An updated review. Pharmaceutical Methods 2010;1:25-38.
18. Endrenyi L, Schulz M: Individual variation and the acceptance of average bioequivalence. Drug Inform J 1993; 27:195-201.
19. U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research: Guidance for Industry: Statistical Approaches to Establishing Bioequiva-lence. Edited by the Office of Training and Communications DoCM, Drug Information Branch, HFD-210. U.S. Department of Health and Human Services, Rockville, MD, 2001.
20. Dezzutti CS, Russo J, Rohan LC, Wang L, Swanson M, Chateau M, and McGowan I: Rectal-specific 1% tenofovir (TFV) gel protects rectal biopsies from infection with HIV-1 transmitted/founder viruses [Abstract]. In International Conference of Microbicides, Sydney, Australia, 2012.
21. Wild D: The Immunoassay Handbook, 2nd ed. Nature Pub. Group, London, 2001.
22. Hladik F and Doncel GF: Preventing mucosal HIV transmission with topical microbicides: Challenges and opportunities. Antiviral Res 2010;88(Suppl 1):S3-9.